On the contrary, Parkinson’s disease is the second most common neurodegenerative disorder across the globe. Patients suffering from Parkinson’s disease face progressive deterioration of motor function that occurs over a period of time due to the loss of brain cells that produce dopamine. In-spite of being the second most common neurodegenerative disorder (after Alzheimer’s), the market for this disease is relatively small, as the definite cause and treatment is unknown. This has opened up new avenues for the use neurological biomarkers. The neurological biomarkers market for Alzheimer’s and Parkinson’s diseases is studied across the U.S., EU5, rest of Europe, China, Asia-Pacific, and rest of the world (ROW).
The study provides an in-depth analysis of the neurological biomarkers market, with current trends and future estimations regarding Alzheimer’s and Parkinson’s.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
Strategies recorded by the key players are analyzed thoroughly to understand the competitive outlook of the market.
Porter’s Five Forces model is expected to interpret the bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition among the key players.
KEY MARKET SEGMENTS
Rest of Europe
KEY MARKET PLAYERS
Thermo Fisher Scientific
Immunarray Pvt. Ltd.
The OTHER PLAYERS in the value chain include (profiles not included in the report)
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
1.4.4. Key assumptions
1.4.5. Key experts
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top winning strategies
3.3. Overall Diagnostic Market Size
3.3.1. Total diagnostic market size by diagnostic techniques
3.4. Incidence, Mortality, Diagnosis Rate, Prevalence Rate and Treatment Rate for Alzheimers And Parkinsons Disease
3.4.1. Incidence rate
3.4.3. Diagnosis rate
3.4.4. Prevalence rate
3.4.5. Treatment rate
3.5. Porters five forces analysis
3.6. Market dynamics
18.104.22.168. Increasing focus on developing cost-effective biomarker testing
22.214.171.124. Rising demand for non-invasive diagnostic techniques for Alzheimers and Parkinsons
126.96.36.199. Increase in the adoption of neurological biomarkers in clinical trials
188.8.131.52. Stringent government regulations
184.108.40.206. Emerging ethical issues regarding early diagnosis of Alzheimers and Parkinsons
220.127.116.11. Rise in the demand for personalized medicine
CHAPTER 4: ALZHEIMER'S DISEASE BIOMARKERS MARKET, BY REGION
4.1.1. Market size and forecast
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.4. Rest of Europe
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast
4.6.1. Key market trends and opportunities
4.6.2. Market size and forecast
4.7. Rest of World (ROW)
4.7.1. Key market trends and opportunities
4.7.2. Market size and forecast
CHAPTER 5: PARKINSONS DISEASE BIOMARKERS MARKET, BY REGION
5.1.1. Market size and forecast
5.2.1. Key market trends and opportunities
5.2.2. Market size and forecast
5.3.1. Key market trends and opportunities
5.3.2. Market size and forecast
5.4. Rest of Europe
5.4.1. Key market trends and opportunities
5.4.2. Market size and forecast
5.5.1. Key market trends and opportunities
5.5.2. Key market trends and opportunities
5.5.3. Market size and forecast
5.6.1. Key market trends and opportunities
5.6.2. Market size and forecast
5.7.1. Key market trends and opportunities
5.7.2. Market size and forecast
The neurological biomarkers market for Alzheimers disease generated a revenue of $2,636.7 million in 2017, and is expected to reach $6,122.5 million by 2025, registering a CAGR of 11.1% from 2018 to 2025. Conversely, neurological biomarkers market for Parkinsons disease generated a revenue of $1,321.8 million in 2017, and is expected to reach $2,457.4 million by 2025 registering a CAGR of 8.0%.
Upsurge in the incidence of Alzheimers and Parkinsons diseases is anticipated to contribute to the robust growth of neurological biomarkers. In addition, increase in adoption of neurological biomarkers in drug development and validation has been witnessed over the years to improve the accuracy of clinical trials. Furthermore, rise in preference towards aerosolized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimers and Parkinsons.
Based on the region, the neurological biomarkers market for Alzheimers and Parkinsons diseases is studied across the U.S., EU5, rest of Europe, Chi, Asia-Pacific, and rest of the world (ROW). The U.S. dominated the market for Alzheimers and Parkinsons in 2017, and is expected to continue this trend throughout the forecast period. In addition, Asia-Pacific is anticipated to grow at the fastest pace in Alzheimers neurological biomarkers market during the forecast period, whereas Chi is expected to register highest growth rate from 2018 to 2025 in the Parkinsons neurological biomarkers market.
Key Findings of the Neurological Biomarkers Market:
Asia-Pacific is expected to register the highest growth rate from 2018 to 2025 in the neurological biomarkers market for Alzheimers.
The U.S. accounted for maximum revenue in 2017 in the market for both Alzheimers and Parkinsons, and is anticipated to maintain this trend throughout the forecast period.
EU5 region generated second highest revenue in 2017 in the market for both Alzheimers & Parkinsons, and is expected to continue this trend throughout the forecast period.
Chi is estimated to exhibit the highest CAGR of 10.1% from 2018 to 2025 in the neurological biomarkers market for Parkinsons disease.
The major companies profiled in this report include Abbott Laboratories, Myriad RBM, Proteome Sciences, Thermo Fisher Scientific, Athe Diagnostics, Immurray Pvt. Ltd.,
Quanterix Corporation, Diagenic ASA, Psynova Neurotech, and Bio-Rad Laboratories. Other prominent players in the value chain include Qiagen, AbaStar MDx, Acumen Pharmaceuticals, Abiant, Alseres Pharmaceuticals, Athe Diagnostics, Banyan Biomarkers, and ProteoSys AG.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.